BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lim TS, Rhee H, Kim GM, Kim SU, Kim BK, Park JY, Ahn SH, Han K, Choi J, Kim DY. Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2019;30:1194-1200.e1. [DOI: 10.1016/j.jvir.2019.03.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Park C, Chu HH, Kim JH, Kim SY, Alrashidi I, Gwon DI, Yoon HK, Kim N. Clinical Significance of the Initial and Best Responses after Chemoembolization in the Treatment of Intermediate-Stage Hepatocellular Carcinoma with Preserved Liver Function. J Vasc Interv Radiol 2020;31:1998-2006.e1. [PMID: 32988715 DOI: 10.1016/j.jvir.2020.04.017] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]
2 Hyun HK, Cho EJ, Park SY, Hong YM, Kim SS, Kim HY, Heo NY, Park JG, Sinn DH, Kang W, Jeong SW, Song MJ, Park H, Lee D, Lee YS, Cho SB, An CS, Rhee HJ, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Lee JH, Yu SJ, Kim YJ, Yoon JH, Tak WY, Kweon YO, Yoon KT, Cho M, Cheong JY, Park SH, Kim SU; Korean TACE Study Group. Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. Dig Dis Sci 2021;66:2427-38. [PMID: 32856240 DOI: 10.1007/s10620-020-06533-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Yang Y, Li G, Lu Z, Liu Y, Kong J, Liu J. Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma. Front Oncol 2021;11:726213. [PMID: 34900676 DOI: 10.3389/fonc.2021.726213] [Reference Citation Analysis]
4 Tan J, Tang T, Zhao W, Zhang ZS, Xiao YD. Initial Incomplete Thermal Ablation Is Associated With a High Risk of Tumor Progression in Patients With Hepatocellular Carcinoma. Front Oncol 2021;11:760173. [PMID: 34733792 DOI: 10.3389/fonc.2021.760173] [Reference Citation Analysis]
5 Pan Y, Chen H, Yu J. Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives. Biomedicines 2020;8:E576. [PMID: 33297335 DOI: 10.3390/biomedicines8120576] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Uygun ZO. State-of-the-art Hepatocellular Carcinoma Biomarker Detection by Biosensor Technology-a Review. J Gastrointest Cancer 2021;52:1081-5. [PMID: 34347247 DOI: 10.1007/s12029-021-00680-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Sun X, Mei J, Lin W, Yang Z, Peng W, Chen J, Zhang Y, Xu L, Chen M. Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients. BMC Cancer 2021;21:775. [PMID: 34218801 DOI: 10.1186/s12885-021-08428-w] [Reference Citation Analysis]
8 Liu DM, Leung TW, Chow PK, Ng DC, Lee RC, Kim YH, Mao Y, Cheng YF, Teng GJ, Lau WY. Clinical consensus statement: Selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia. Int J Surg 2022;102:106094. [PMID: 35662438 DOI: 10.1016/j.ijsu.2021.106094] [Reference Citation Analysis]
9 Zhou Z, Han X, Sun D, Liang Z, Wu W, Ju H. A Comprehensive Prognostic Model for Colorectal Cancer Liver Metastasis Recurrence After Neoadjuvant Chemotherapy. Front Oncol 2022;12:855915. [DOI: 10.3389/fonc.2022.855915] [Reference Citation Analysis]